SD-254

Details

Stereochemistry	RACEMIC
Molecular Formula	C17H27NO2
Molecular Weight	286.4572
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[2H]C([2H])([2H])OC1=CC=C(C=C1)C(CN(C([2H])([2H])[2H])C([2H])([2H])[2H])C2(O)CCCCC2

InChI

InChIKey=PNVNVHUZROJLTJ-GQALSZNTSA-N

InChI=1S/C17H27NO2/c1-18(2)13-16(17(19)11-5-4-6-12-17)14-7-9-15(20-3)10-8-14/h7-10,16,19H,4-6,11-13H2,1-3H3/i1D3,2D3,3D3

HIDE SMILES / InChI

Molecular Formula	C17H27NO2
Molecular Weight	286.4572
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Approval Year

Substance Class	Chemical Created by `admin` on `Sat Dec 16 11:43:09 UTC 2023` Edited by `admin` on `Sat Dec 16 11:43:09 UTC 2023`
Record UNII	OG81QLX6OF
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SD-254

Code

English

SD 254

Code

English

CYCLOHEXANOL, 1-(2-(DI(METHYL-D3)AMINO)-1-(4-(METHOXY-D3)PHENYL)ETHYL)-

Systematic Name

English

VENLAFAXINE DEUTERIUM-SUBSTITUTED

Common Name

English

D9-VENLAFAXINE

Common Name

English

1-(2-(BIS(TRIDEUTERIOMETHYL)AMINO)-1-(4-(TRIDEUTERIOMETHOXY)PHENYL)ETHYL)CYCLOHEXANOL

Systematic Name

English

Code System Code Type Description

PUBCHEM

24936230

Created by admin on Sat Dec 16 11:43:09 UTC 2023 , Edited by admin on Sat Dec 16 11:43:09 UTC 2023

PRIMARY

FDA UNII

OG81QLX6OF

Created by admin on Sat Dec 16 11:43:09 UTC 2023 , Edited by admin on Sat Dec 16 11:43:09 UTC 2023

PRIMARY

CAS

940297-30-3

Created by admin on Sat Dec 16 11:43:09 UTC 2023 , Edited by admin on Sat Dec 16 11:43:09 UTC 2023

PRIMARY

Related Record Type Details


					CC02PGHFLC

SD-254 HYDROCHLORIDE

SALT/SOLVATE -> PARENT

Related Record Type Details


					OG81QLX6OF

SD-254

ACTIVE MOIETY

Comments:

Company: Teva Pharmaceutical Industries Ltd.; Description: Deuterium-substituted version of venlafaxine, a selective serotonin-norepinephrine reuptake inhibitor (SNRI); Molecular Target: Serotonin (5-HT) transporter (SLC6A4) (SERT), Norepinephrine transporter; Mechanism of Action: Norepinephrine reuptake inhibitor; Selective serotonin reuptake inhibitor (SSRI); Therapeutic Modality: Small molecule Originator: Auspex Pharmaceuticals; Class: Antidepressant, Cyclohexanol, Dimethylamine, Organic deuterium compound, Small molecule; Mechanism of Action: Adrenergic receptor antagonist, Serotonin uptake inhibitor; Highest Development Phase: No development reported for Major depressive disorder, Discontinued for Neuropathic pain; Most Recent Events: 15 Jan 2015 Discontinued - Phase-I for Neuropathic pain in USA (PO), 15 Jul 2013 Phase-I clinical trials in Neuropathic pain in USA (PO), 24 Oct 2010 No development reported - Phase-I for Major depressive disorder in USA (PO)